UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD

ELI LILLY AND COMPANY v. TEVA PHARMACEUTICALS INTERNATIONAL GMBH

Case IPR2018-01422 (Patent No. 9,340,614) Case IPR2018-01423 (Patent No. 9,266,951)

Case IPR2018-01424 (Patent No. 9,346,881)

Case IPR2018-01425 (Patent No. 9,890,210)

Case IPR2018-01426 (Patent No. 9,890,211)

Case IPR2018-01427 (Patent No. 8,597,649)*

ELI LILLY TRIAL DEMONSTRATIVES

November 22, 2019



Eli Lilly Trial Demonstratives

I.	Summary of Case
II.	Overview of Challenged Patent Claims
III.	Overview of Asserted References
	Additional Motivation from Prior Art
V.	Teva Failed to Rebut Motivation
	Reasonable Expectation of Success
	Alleged Secondary Considerations
	Teva's Affinity Claims Are Obvious
	Detailed Analysis
	Motion to Strike
	Motion to Exclude




Summary of Case

- Teva's patents broadly claim any humanized anti-CGRP antagonist an with known or routinely achievable features
- Tan 1995 describes an anti-CGRP antagonist antibody effective in vivo provides guidance to improve immunoblockade
- Wimalawansa expressly teaches that humanized anti-CGRP antibodie "should be explored" to treat human diseases
- The prior art is replete with reports providing additional motivation t a humanized anti-CGRP antagonist antibody
- Teva conceded it was routine to make a humanized antibody
- Neither Tan 1995 nor Teva's purported safety concerns teach away fr claimed subject matter
- Teva's purported secondary considerations lack nexus and are insuffi overcome obviousness



The Breadth of Teva's Claims





Tan 1995 (Ex. 1022) Shows MAb C4.19 Was Effective I

Date Street (1975, 88, 163-57) (French in Great Street) Calcitonin gene-related peptide as an endogenous vasodilator: immunoblockade studies in vivo with an anti-calcitonin gene-related peptide monoclonal antibody and its Fab fragment But K. C. TAN, Morris J. BROWN, Richard J. HARGREAVESY, Sars L. SHERHEARDS,

Search A COOK? and Raymond G. HELL?

Direct Phornacology Unit, University of Combridge Consul School, Addesbrook's Phopses, Gestridge, U.K., and TMCryk Storp and Dahme Research Laboratores. Neuroscoloce Research Sees, Horlow, Essex, U.K.

nel (FjorellAugus (WC sciented til Augus (WE

1. Calcitonia gene-related peptide (CGRP) is local-ind in privascular sensory reserves and is a petent wouldate. We irrestigated the utility of insuran-lickale as as in vivo technique for probing the role (CCRP) as a sensor of the contract of the probing of the con-

technic as an in vivo technique for probing the role of CGFP on endogramos vasodilator.

The effects of an anti-CGFP mesockoral artifold StAts coded CA19 and its Fab' fragment on CGFP-induced changes in blood present and skin food fine were studied in periodial blood fine were studied in periodial blood membrated rats. Autiflutions, skin raconfidatation in the skind pare was measured by laser Dopplet Smooth.

training. The done-response relationship for the hypotensia-for of intravenous rat of GRP (see CGP) was maked whited eight-ward by MAA CA19 IgG ingless, intravenously) and Fab frequence legistes, intravenously). The Convenient frequence of man af CGP (In CGRP₂₋₁₋₁) also blacked the polassis effects of sec GRP₂₋₁₋₁ also blacked the polassis effects of sec GRP₂₋₁₋₁ also blacked in polassis effects of sec GRP₂₋₁₋₁ also blacked in many and hard GRP₂₋₁ (100 monthly) increa-mently, but not MAA CA19 IgG (up to Jungitus, intravenously) to introduce the increased white hard free response to antidromic selectation of the spinson acres.

of this proposition to automotion, the form terrise. Because the form terrise the seaso percentage changes in skin blood flow terrises due to MAA CA19 Fall fragment are solutionly different from those due to result from those due to her CAP per the fall fragment impaired r-nest P = 0.00° has film those due to her CAP per the results demonstrate the pharmaconicus demonstrate of Fall fragment over IgG for immuno-

CGRP in mediating skin varieble

Calcules a gree-related popular (CURP) in lac-

Calcones gene-related peptide (CORPT in Incalture in previouslar primary offerest heatons said on
a pointst viscolitary in man and it all summaspecies studied [1]—3. Some militarios of the
supercurrie of CORPT in the regulation of the
supercurrie of CORPT in the regulation of the
supercurries of CORPT in the regulation of the
supercurries of CORPT in the regulation of those
8-37. The propose of the control of the supercurries
52. The hypotension should be related in the
bit in Accordance of the control of the
in an assorbitation and consource to the
in the GORP 2, 16, 17, Europeans
a systamed hypotension should be in the
lesson and companies CORPT are malegorous.
The control of the control of the
print causellistation after spenies to be
to see stope measured and the species may be
less of the CORPT 2, 1900 the
control of the control of the supercurrent in the substance of the supercurrent in the control of the supercurrent in the control of the supercurrent that CORPT 2 are response to the
supercurrent that control of the supercurrent that CORPT 2 are response to the
supercurrent that control of the supercurrent that CORPT 2 are response to the
supercurrent that control of the supersupercurrent that CORPT 2 are response
to the control of the supercurrent that CORPT 2 are response
to the control of the supercurrent that control of the
supercurrent that control of the supercurrent that control

The control of the supercurrent that the supercurrent that control

The control of the supercurrent that the supercurrent that control

The control of the supercurrent that the supercurrent that control

The control of the supercurrent that the supercurrent t

This study has clearly demonstrated the MAb C4.19 IgG and its Fab' fragment to hypotensive effects of exogenous raCGR

Ex. 1022, 570; Ex. 100

to CGRP. MAb C4.19 does not cross-react amylin in vitro but the potential of MAb (

Ex. 1022, 572; Ex. 1009



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

